Company intelligence / Profile preview

TAA05 Cell

Shanghai, China

Ownership: Private
Development stage: Other

Overview

TAA05 Cell is a clinical-stage biotechnology company focused on the development of innovative chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors. The company's lead program, TAA05, is an autologous CAR-T cell therapy targeting Glypican-3 (GPC3), which is highly expressed in hepatocellular carcinoma. TAA05 Cell aims to overcome the challenges of treating solid tumors with cell therapies by utilizing advanced genetic engineering to enhance T-cell infiltration and persistence within the tumor microenvironment. The company is currently conducting early-phase clinical trials to evaluate the safety and efficacy of its candidates in patients with advanced liver cancer.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on TAA05 Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAA05 Cell.

Explore the full profile